Fassnacht M - Search Results

1

Werner RA, Schirbel A, Buck AK, Fassnacht M, Hahner S. Werner RA, et al. Among authors: fassnacht m. Presse Med. 2022 Jun;51(2):104114. doi: 10.1016/j.lpm.2022.104114. Epub 2022 Feb 4. Presse Med. 2022. PMID: 35131316

2

New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.

Fassnacht M, Hahner S, Beuschlein F, Klink A, Reincke M, Allolio B. Fassnacht M, et al. Eur J Clin Invest. 2000 Dec;30 Suppl 3:76-82. doi: 10.1046/j.1365-2362.2000.0300s3076.x. Eur J Clin Invest. 2000. PMID: 11281374 Review.

3

Clodronate inhibits adrenocortical cell proliferation and P450c21 activity.

Fassnacht M, Franke A, Dettling A, Hahner S, Zink M, Wudy S, Allolio B. Fassnacht M, et al. J Endocrinol. 2002 Sep;174(3):509-16. doi: 10.1677/joe.0.1740509. J Endocrinol. 2002. PMID: 12208672

4

N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis.

Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair J, Allolio B. Fassnacht M, et al. J Clin Endocrinol Metab. 2003 May;88(5):2171-9. doi: 10.1210/jc.2002-021318. J Clin Endocrinol Metab. 2003. PMID: 12727972

5

The adrenal secretory serine protease AsP is a short secretory isoform of the transmembrane airway trypsin-like protease.

Hansen IA, Fassnacht M, Hahner S, Hammer F, Schammann M, Meyer SR, Bicknell AB, Allolio B. Hansen IA, et al. Among authors: fassnacht m. Endocrinology. 2004 Apr;145(4):1898-905. doi: 10.1210/en.2003-0930. Epub 2003 Dec 22. Endocrinology. 2004. PMID: 14691009

6

Management of adrenocortical carcinoma.

Allolio B, Hahner S, Weismann D, Fassnacht M. Allolio B, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87. doi: 10.1046/j.1365-2265.2003.01881.x. Clin Endocrinol (Oxf). 2004. PMID: 15008991 Review.

7

Evidence against a role of human airway trypsin-like protease--the human analogue of the growth-promoting rat adrenal secretory protease--in adrenal tumourigenesis.

Hahner S, Fassnacht M, Hammer F, Schammann M, Weismann D, Hansen IA, Allolio B. Hahner S, et al. Among authors: fassnacht m. Eur J Endocrinol. 2005 Jan;152(1):143-53. doi: 10.1530/eje.1.01834. Eur J Endocrinol. 2005. PMID: 15762198

8

AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors.

Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B. Fassnacht M, et al. J Clin Endocrinol Metab. 2005 Jul;90(7):4366-70. doi: 10.1210/jc.2004-2198. Epub 2005 Apr 26. J Clin Endocrinol Metab. 2005. PMID: 15855265

9

Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.

Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F; German and Austrian Adrenal Network. Betz MJ, et al. Among authors: fassnacht m. J Clin Endocrinol Metab. 2005 Jul;90(7):3886-96. doi: 10.1210/jc.2004-1267. Epub 2005 May 10. J Clin Endocrinol Metab. 2005. PMID: 15886257

10

Mitotane for adrenocortical carcinoma treatment.

Hahner S, Fassnacht M. Hahner S, et al. Among authors: fassnacht m. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. Curr Opin Investig Drugs. 2005. PMID: 15898346 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page